Navigation Links
Aton Pharma Announces Distribution Partnership in Brazil
Date:5/12/2008

LAWRENCEVILLE, N.J., May 12 /PRNewswire/ -- Aton Pharma, Inc., a global specialty pharmaceutical company, announced today that it has signed a distribution agreement with Meizler Biopharma S/A to commercialize CUPRIMINE(R) and SYPRINE(R) in Brazil. Cuprimine is currently approved in Brazil, and Meizler is working to obtain regulatory approval of Syprine.

"Cuprimine and Syprine are medically essential products, and Aton is committed to making these products available wherever they are needed," said Michael G. Wells, Chief Executive Officer of Aton Pharma. "Brazil is the largest country in Latin America, and we are very pleased that we found Meizler to help us address the needs of patients in this country."

"Meizler has a long history of providing important medical therapies in Brazil," stated Avi Meizler, Meizler's President. "Cuprimine and Syprine both perfectly complement our current portfolio, and we look forward to helping Aton expand their presence in Brazil."

Meizler is a Brazilian Pharmaceutical company, headquartered in Sao Paulo, active in both the out-patient and hospital segments of the pharmaceutical industry. The company currently markets more than 40 products on the Brazilian market and has international partnerships in place with companies in the United States, Europe and Asia, to which Meizler provides various regulatory and commercial services. Using an advanced management and logistics system, Meizler is able to rapidly supply its high quality products to providers and patients. For more information, see http://www.meizler.com.br.

About Aton Pharma, Inc.

Aton Pharma, Inc., headquartered in Lawrenceville, NJ, is a global specialty pharmaceutical company providing essential treatments for under- treated diseases and rare illnesses around the world. Aton's mission is to improve patient outcomes and quality of life worldwide by enhancing and expanding access and availability of medically essential therapeutics. Aton's portfolio of seven products, with sales in over 30 countries, targets rare and orphan metabolic, neurological, cardiovascular and ophthalmic diseases. For more information, see http://www.atonrx.com.

CONTACT: Ed Stevens, 727-327-3396, Estevens3@tampabay.rr.com


'/>"/>
SOURCE Aton Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset Selected to Join the NASDAQ Biotechnology Index
2. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
3. NuRx Pharmaceuticals Announces Change of Ticker Symbol to NUXP, Reverse Stock Split Now in Effect
4. Amylin Pharmaceuticals to Present at Baird Growth Stock Conference
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
6. Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
7. EUSA Pharma Completes Acquisition Of Cytogen Corporation
8. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
9. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
11. Onyx Pharmaceuticals to Present at Bank of America Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... genomics analysis platform specifically designed for life science researchers to analyze and ... researcher Rosalind Franklin, who made a major contribution to the discovery of ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... it will be hosting a Webinar titled, “Pathology is going digital. Is your ... on digital pathology adoption best practices and how Proscia improves lab economics and ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... , Oct. 10, 2017 International research firm Parks ... Strategy, will speak at the TMA 2017 Annual Meeting , October ... trends in the residential home security market and how smart safety and ... Parks ... "The residential ...
Breaking Biology Technology:
(Date:5/6/2017)... , May 5, 2017 ... just announced a new breakthrough in biometric authentication ... exploits quantum mechanical properties to perform biometric authentication. These ... smart semiconductor material created by Ram Group and ... finance, entertainment, transportation, supply chains and security. Ram ...
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/13/2017)... April 13, 2017 According to a new market ... Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, ... Market is expected to grow from USD 14.30 Billion in 2017 to ... of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):